AM Best’s Annual Europe Insurance Market Briefing in London to Focus on Implications of Heightened Geopolitical Tensions for (Re)Insurers; Lloyd’s Chief of Market Performance to Deliver Keynote

AM Best will hold its annual Europe Insurance Market Briefing on 5 November 2026, from 8:30 a.m. to 3:45 p.m. GMT, in London. Lloyd’s of London chief of market performance Rachel Turk is scheduled to deliver a keynote on managing geopolitical risks; the programme will also examine European insurance markets amid rising cross-border conflicts.

Analysis

This is a calendar item, not new evidence of higher insured losses, tighter capacity, or improved pricing. The near-term market impact should therefore be negligible. The useful signal is whether public discussion translates into observable underwriting changes: war-risk exclusions, higher rates, reduced limits, or greater demand for reinsurance. Those changes could benefit reinsurers such as Munich Re, Swiss Re, and Hannover Re if they retain pricing discipline, but could also constrain growth if capital or risk appetite becomes the binding limit. European primary insurers could face higher claims volatility or ceded-reinsurance costs; brokers may benefit from more complex placement needs, though that is not established by the announcement.

Over the next 1–3 months, treat the event as a potential source of commentary, not a catalyst by itself. Over 6–18 months, the thesis matters only if geopolitical risk produces persistent repricing or changes to coverage and capital allocation. Contrarian point: attention to geopolitical risk can lift expectations before underwriting evidence appears, while actual premium growth may be offset by higher claims, reinsurance costs, or reduced exposure. No trade is warranted on this announcement alone.

Key Decisions for Investors

• No immediate position: the announcement contains no new financial or underwriting data.
• Monitor subsequent insurer and reinsurer disclosures for war-risk rate changes, exclusions, renewal retention, and reinsurance costs; these are more actionable than conference rhetoric.
• If evidence shows sustained repricing without a corresponding deterioration in loss trends, reassess European reinsurers versus primary insurers; do not assume the benefit is uniform across the sector.
• Falsify any constructive pricing thesis if companies report weaker renewal terms, rising loss costs that absorb rate gains, or reduced appetite/capacity in exposed lines.